[Featured Stock] Peptron Announces Clinical Plans for Diabetes and Obesity Treatments... Rises for 2 Consecutive Trading Days

Peptron is showing strong performance on the 28th.

According to the Korea Exchange on the 28th, as of 1:20 PM, Peptron is trading at 84,200 KRW, up 5.65% (4,500 KRW) from the previous trading day.

Peptron recorded an all-time high closing price of 131,000 KRW on the 15th, but its stock price slid to the 70,000 KRW range due to deteriorating supply and demand in the biopharmaceutical sector. However, it rebounded by continuing an upward trend for two consecutive trading days through this day.

Shinhan Investment Corp. evaluated positively that Peptron announced plans for Phase 1 clinical trials of its diabetes and obesity treatment (PT404) at its corporate presentation.

Minyong Eom, a researcher at Shinhan Investment Corp., said, "The scheduled listing date for new shares from the paid-in capital increase is the 4th of next month, and the supply overhang concerns worsened supply and demand, affecting the stock price. Although the recent weakening of investor sentiment in the pharmaceutical and bio sector also had an impact, it is important to look at the positive content of the company's corporate presentation."

He added, "The most positive aspect of this announcement is that Peptron revealed plans for Phase 1 clinical trials of PT404 regardless of the main contract status. It was confirmed in the disclosure that the technology review contract involves 'drugs,' and through this corporate presentation, it was confirmed that at least PT404 will enter Phase 1 clinical trials in 2025. If the two companies complete their decision on dosing in the first half of next year, it is expected that the main contract will be signed."

Earlier, Peptron announced last month that it had signed a platform technology evaluation contract with Eli Lilly. They plan to conduct joint research applying Peptron's 'Smart Depot' platform technology to peptide drugs owned by Eli Lilly. Peptide drugs have a short half-life and require frequent injections. Peptron's Smart Depot technology extends the drug efficacy, increasing the frequency of peptide injections from once a week to once every six months.